FDA
-
-
-
-
-
-
-
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
-
-
-
-
-
-
-
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
-
-
-
-
-
-
-
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
-
-
-
-
-
-
335,223 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


